Akihiko Miyanaga

15PUBLICATIONS
33CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classifiedMolecular targetsCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Aug 22, 2026
Aberrant expression of the PREX2-MAGI2 axis modulates myofibroblast differentiation in pulmonary fibrosis.

|Mar 17, 2025
Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study.

Fumihiko Kinoshita, Shigeru Tanzawa, Toshihiro Misumi

|Feb 17, 2025
Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study.

Shigeru Tanzawa, Hiroshige Yoshioka, Toshihiro Misumi

|Jan 13, 2025
Lung Cancer in Non-Smokers.

Akihiko Miyanaga, Masahiro Seike

|Jun 28, 2024
Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR-mutated NSCLC with high thrombospondin-1 expression.

Naomi Onda, Shinji Nakamichi, Mariko Hirao

|Jun 26, 2024
Induction of resistance to neurotrophic tropomyosin-receptor kinase inhibitors by HMGCS2 via a mevalonate pathway.

Yasuhiro Kato, Masaru Matsumoto, Natsuki Takano

Pageof 3

Frequent Collaborators

5 joint publications

Takehiro Tozuka

4 joint publications

Rintaro Noro

3 joint publications

Yasuhiro Terasaki

3 joint publications

Satoshi Watanabe